

Crescens Tiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2641379/publications.pdf>

Version: 2024-02-01

8
papers

39
citations

2258059

3
h-index

1872680

6
g-index

8
all docs

8
docs citations

8
times ranked

63
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. <i>Clinical Cancer Research</i> , 2020, 26, 4805-4813.	7.0	12
2	Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103225.	4.4	10
3	A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. <i>Lancet Oncology</i> , 2020, 21, 889-891.	10.7	4
4	Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 190-194.	1.1	3
5	Outcomes of Australian patients receiving non-funded anti-PD immune checkpoint inhibitors for non-melanoma cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 337-342.	1.1	3
6	A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 189-195.	1.4	3
7	Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. <i>Oncology</i> , 2019, 97, 270-276.	1.9	2
8	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100309.	1.7	2